Cambridge, Massachusetts – Luminopia, a leading biotechnology company, announced today the successful completion of its Series A funding round, raising an impressive $16,000,000. The funding round was led by U.S. Venture Partners and ShangBay Capital, two prominent venture capital firms with a strong track record of supporting innovative healthcare solutions.

Luminopia has emerged as a pioneer in the field, revolutionizing treatments for significant neuro-visual disorders. The company's mission is to develop and deliver digital therapeutics that not only undergo rigorous evaluation for FDA approval but also engage patients in a meaningful and enjoyable manner.

As an esteemed Innovation Partner of Boston Children's Hospital, Luminopia is dedicated to addressing one of the most prevalent neuro-visual disorders affecting children – amblyopia, commonly known as lazy eye. Amblyopia is the leading cause of vision loss among children and often requires early intervention to prevent long-term vision impairment. Luminopia's cutting-edge lead product aims to transform the treatment landscape for amblyopia and provide children with a brighter future.

"We are grateful to have the support of U.S. Venture Partners and ShangBay Capital in this significant milestone for Luminopia," said Scott Xiao, Co-Founder of Luminopia. "This funding will play a pivotal role in advancing our groundbreaking treatments for neuro-visual disorders, with a focus on our lead product targeting amblyopia. Our collaboration with Boston Children's Hospital has been invaluable, and we are excited to continue our mission of transforming the lives of children with vision impairments."